A novel PIBF1-RET gene fusion identified from a stage IA lung adenocarcinoma: A case report

Rearranged during transfection (RET) gene fusions occur in 0.7% to 2% in lung cancer and 1% to 2% in non-small cell lung cancer. Systemic therapies for RET fusion-positive non-small cell lung cancer consist mostly of targeted therapy with RET inhibitors such as selpercatinib and pralsetinib. To date...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Weidi, Sun, Jia’en, Zhu, Huangkai, Zhao, Guofang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662845/
https://www.ncbi.nlm.nih.gov/pubmed/37478265
http://dx.doi.org/10.1097/MD.0000000000034305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662845/
https://www.ncbi.nlm.nih.gov/pubmed/37478265
http://dx.doi.org/10.1097/MD.0000000000034305

Ejemplares similares